JP2011527667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527667A5 JP2011527667A5 JP2011513994A JP2011513994A JP2011527667A5 JP 2011527667 A5 JP2011527667 A5 JP 2011527667A5 JP 2011513994 A JP2011513994 A JP 2011513994A JP 2011513994 A JP2011513994 A JP 2011513994A JP 2011527667 A5 JP2011527667 A5 JP 2011527667A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- tetrahydro
- methoxy
- pyrimido
- ylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- -1 phenyl cyclopropyl Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- XJDFPABNFMGUQZ-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-phenylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(F)(F)CN2CCC1=CC=CC=C1 XJDFPABNFMGUQZ-UHFFFAOYSA-N 0.000 claims 1
- TUQMYIJNTSGUGF-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-phenylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(oxan-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCOCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(F)(F)CN2CCC1=CC=CC=C1 TUQMYIJNTSGUGF-UHFFFAOYSA-N 0.000 claims 1
- PSUBGYPXALNCMG-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-phenylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3C=CC=CC=3)C2=N1 PSUBGYPXALNCMG-UHFFFAOYSA-N 0.000 claims 1
- XSDGPZQANIZACZ-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-phenylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3C=CC=CC=3)C2=N1 XSDGPZQANIZACZ-UHFFFAOYSA-N 0.000 claims 1
- PCPAXXKTKQUPHR-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-phenylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3C=CC=CC=3)C2=N1 PCPAXXKTKQUPHR-UHFFFAOYSA-N 0.000 claims 1
- NGAFYUZTCNBCGI-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-phenylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCCN(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3C=CC=CC=3)C2=N1 NGAFYUZTCNBCGI-UHFFFAOYSA-N 0.000 claims 1
- KVBACVCSBJSAER-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-thiophen-2-ylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(F)(F)CN2CCC1=CC=CS1 KVBACVCSBJSAER-UHFFFAOYSA-N 0.000 claims 1
- DGGHCJPFKMNPAU-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-thiophen-2-ylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(oxan-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCOCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(F)(F)CN2CCC1=CC=CS1 DGGHCJPFKMNPAU-UHFFFAOYSA-N 0.000 claims 1
- JSFTXPUPTJTYTB-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-thiophen-2-ylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3SC=CC=3)C2=N1 JSFTXPUPTJTYTB-UHFFFAOYSA-N 0.000 claims 1
- KMWJCCMWYIKRNP-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-thiophen-2-ylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3SC=CC=3)C2=N1 KMWJCCMWYIKRNP-UHFFFAOYSA-N 0.000 claims 1
- MNHDFLRMCRZSOS-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-thiophen-2-ylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCCN(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3SC=CC=3)C2=N1 MNHDFLRMCRZSOS-UHFFFAOYSA-N 0.000 claims 1
- QIMBUKMFWMBEHR-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(3-phenylpropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(F)(F)CN2CCCC1=CC=CC=C1 QIMBUKMFWMBEHR-UHFFFAOYSA-N 0.000 claims 1
- PHXLWWFFQDNSSE-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(3-phenylpropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(oxan-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCOCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(F)(F)CN2CCCC1=CC=CC=C1 PHXLWWFFQDNSSE-UHFFFAOYSA-N 0.000 claims 1
- DMMUXYAYHYDDLV-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(3-phenylpropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCCC=3C=CC=CC=3)C2=N1 DMMUXYAYHYDDLV-UHFFFAOYSA-N 0.000 claims 1
- UXZZINQYOKUPEO-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(3-phenylpropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCCC=3C=CC=CC=3)C2=N1 UXZZINQYOKUPEO-UHFFFAOYSA-N 0.000 claims 1
- XXIJBRADQSRHDK-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(3-phenylpropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCCC=3C=CC=CC=3)C2=N1 XXIJBRADQSRHDK-UHFFFAOYSA-N 0.000 claims 1
- GHTYTXXJOCCCQB-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(3-phenylpropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCCN(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCCC=3C=CC=CC=3)C2=N1 GHTYTXXJOCCCQB-UHFFFAOYSA-N 0.000 claims 1
- QREWJFAVPDUZPY-LADGPHEKSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-[(1r,2s)-2-phenylcyclopropyl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound C1([C@@H]2C[C@H]2N2CC(F)(F)C(=O)N(C)C3=CN=C(N=C32)NC2=CC=C(C=C2OC)C(=O)NC2CCN(C)CC2)=CC=CC=C1 QREWJFAVPDUZPY-LADGPHEKSA-N 0.000 claims 1
- AVYWETQIOGLARX-FUHWJXTLSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-[(1r,2s)-2-phenylcyclopropyl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2[C@H]3[C@@H](C3)C=3C=CC=CC=3)C2=N1 AVYWETQIOGLARX-FUHWJXTLSA-N 0.000 claims 1
- IXGLPNQCLBXUHO-FUHWJXTLSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-[(1r,2s)-2-phenylcyclopropyl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2[C@H]3[C@@H](C3)C=3C=CC=CC=3)C2=N1 IXGLPNQCLBXUHO-FUHWJXTLSA-N 0.000 claims 1
- IWZPVFATWJHPPC-JTHBVZDNSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-[(1r,2s)-2-phenylcyclopropyl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCCN(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2[C@H]3[C@@H](C3)C=3C=CC=CC=3)C2=N1 IWZPVFATWJHPPC-JTHBVZDNSA-N 0.000 claims 1
- GLTMSDBAMFENHK-UHFFFAOYSA-N 4-[[7,7-difluoro-9-[(4-methoxyphenyl)methyl]-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound C1=CC(OC)=CC=C1CN1C2=NC(NC=3C(=CC(=CC=3)C(=O)NC3CCN(C)CC3)OC)=NC=C2N(C)C(=O)C(F)(F)C1 GLTMSDBAMFENHK-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7338808P | 2008-06-18 | 2008-06-18 | |
| US61/073,388 | 2008-06-18 | ||
| PCT/EP2009/057144 WO2009153197A1 (en) | 2008-06-18 | 2009-06-10 | Halo-substituted pyrimidodiazepines as plkl inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011527667A JP2011527667A (ja) | 2011-11-04 |
| JP2011527667A5 true JP2011527667A5 (OSRAM) | 2012-08-02 |
Family
ID=41431858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513994A Abandoned JP2011527667A (ja) | 2008-06-18 | 2009-06-10 | ハロ置換ピリミドジアゼピン |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8003785B2 (OSRAM) |
| EP (1) | EP2303889A1 (OSRAM) |
| JP (1) | JP2011527667A (OSRAM) |
| WO (1) | WO2009153197A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8026234B2 (en) * | 2007-09-25 | 2011-09-27 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| EP2389362B1 (en) | 2009-01-21 | 2019-12-11 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| MX2012003484A (es) * | 2009-09-25 | 2012-04-20 | Vertex Pharma | Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa. |
| CN103492391A (zh) | 2009-09-25 | 2014-01-01 | 沃泰克斯药物股份有限公司 | 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法 |
| BR112012006572A2 (pt) | 2009-09-25 | 2016-04-26 | Oryzon Genomics Sa | inibidores de demetilase-1 de lisina específicos e seu uso |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| JP5504898B2 (ja) * | 2010-01-08 | 2014-05-28 | セントラル硝子株式会社 | ジフルオロシクロプロパン化合物の製造方法 |
| US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
| WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| JP5868948B2 (ja) | 2010-04-19 | 2016-02-24 | オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． | リジン特異的脱メチル化酵素１阻害薬およびその使用 |
| ES2674747T3 (es) | 2010-07-29 | 2018-07-03 | Oryzon Genomics, S.A. | Inhibidores de demetilasa LSD1 basados en arilciclopropilamina y sus usos médicos |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| EP3981395A1 (en) | 2011-02-08 | 2022-04-13 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| RU2668952C2 (ru) | 2011-10-20 | 2018-10-05 | Оризон Дженомикс, С.А. | (гетеро)арилциклопропиламины в качестве ингибиторов lsd1 |
| US8975398B2 (en) | 2012-05-11 | 2015-03-10 | Abbvie Inc. | NAMPT inhibitors |
| MX2016001037A (es) | 2013-07-25 | 2016-11-10 | Dana Farber Cancer Inst Inc | Inhibidores de factores de transcripción y usos. |
| EP3099693A4 (en) * | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| US10150756B2 (en) | 2014-01-31 | 2018-12-11 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| RU2017104897A (ru) | 2014-08-08 | 2018-09-10 | Дана-Фарбер Кэнсер Инститьют, Инк. | Производные диазепана и их применения |
| CN105646398B (zh) * | 2014-12-05 | 2018-09-07 | 上海医药工业研究院 | N-((1r,4r)-4-(4-(环丙基甲基)哌嗪-1-基)环己基)乙酰胺的制备方法 |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| PE20181287A1 (es) | 2015-09-11 | 2018-08-07 | Dana Farber Cancer Inst Inc | Ciano tienotriazolpirazinas y usos de las mismas |
| US10913752B2 (en) | 2015-11-25 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibitors and uses thereof |
| WO2021194318A1 (en) * | 2020-03-27 | 2021-09-30 | Uppthera | Plk1 selective degradation inducing compound |
| WO2022145989A1 (ko) * | 2020-12-31 | 2022-07-07 | (주) 업테라 | 선택적 plk1 억제제로서의 피리미도디아제핀 유도체 |
| EP4157850A4 (en) * | 2021-08-10 | 2024-11-20 | Uppthera, Inc. | Novel plk1 degradation inducing compound |
| GB202313514D0 (en) | 2023-09-05 | 2023-10-18 | Cambridge Entpr Ltd | Treatment of inflammatory diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0303363A2 (hu) | 1999-09-17 | 2004-07-28 | Abbott Gmbh & Co., Kg | Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására |
| JP3876254B2 (ja) | 2001-09-04 | 2007-01-31 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規なジヒドロプテリジノン、その製造方法及びその医薬組成物としての使用 |
| US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| NZ570530A (en) | 2006-02-14 | 2011-09-30 | Vertex Pharma | Pharmaceutical compositions comprising 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4)diazepine derivatives |
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| SI2139892T1 (sl) * | 2007-03-22 | 2011-12-30 | Takede Pharmaceutical Company Ltd | Substituirani pirimidodiazepini, uporabni kot PLK1 inhibitorji |
| US8026234B2 (en) * | 2007-09-25 | 2011-09-27 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
-
2009
- 2009-06-10 EP EP09765777A patent/EP2303889A1/en not_active Withdrawn
- 2009-06-10 JP JP2011513994A patent/JP2011527667A/ja not_active Abandoned
- 2009-06-10 WO PCT/EP2009/057144 patent/WO2009153197A1/en not_active Ceased
- 2009-06-16 US US12/485,108 patent/US8003785B2/en not_active Expired - Fee Related